Webinar – First to Market: Unlocking Switzerland’s Pharma Potential
What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, and evidence requirements? How might the evolving Joint Clinical Assessment (JCA) landscape influence launch sequencing?
On Thursday 16th October we held this live Global Whispers webinar exploring Switzerland’s potential as an early launch market.
In this session, Louise Maddison (Senior Consultant – Global Pricing and Market Access, Petauri Evidence) interviewed Dr Elisabeth Brock (Independent expert in market access in Switzerland), who has extensive experience in Swiss healthcare, including regulatory and payer engagement, dossier preparation for the Swiss Specialities List (SL), and strategic launch planning.
The webinar recording will be released shortly. Please email evidence@petauri.com for more information.
Together, we explorde what global market access teams need to know about launching in Switzerland – from regulatory routes and pricing frameworks to the nuances of payer expectations and evidence generation.
We’ll discussed:
- What makes Switzerland attractive as a first-launch market
- Key differences between Swiss and European Union (EU) market access pathways
- How to prepare for inclusion on the SL and what “economically efficient pricing” really means
- The role of cantonal (state) variation and decentralised healthcare in shaping access
- How Swiss decisions may be influenced by the EU’s JCA
- What global teams can learn from Swiss strategy to inform broader launch planning
More about our speaker:
Dr Elisabeth Brock (Swiss market access/HTA/HEOR specialist, Elibo Health)
Elisabeth has more than 20 years of experience in market access, health technology assessment (HTA), and health economics and outcomes research (HEOR) consulting for Switzerland, providing strategic and operational support to Pharma, Biotech, Device, and Diagnostics clients. She has supported clients across several different reimbursement pathways, covering inpatient as well as outpatient settings. Her experience includes supporting pricing and reimbursement for three ATMPs/gene therapies. Elisabeth has also provided pricing and reimbursement support for several other countries, including Germany, the UK, and Sweden.
The Global Whispers webinar series
This webinar is part of our Global Whispers series where we explore global market access trends and challenges facing the Pharmaceutical and Medtech industries and offer insights into key launch markets.
View more webinars from our Global Whispers series here.
Share